中国医药
中國醫藥
중국의약
CHINA MEDICINE
2014年
8期
1102-1104
,共3页
孙月玲%苑淑丽%孙波%冯福宾%田雪
孫月玲%苑淑麗%孫波%馮福賓%田雪
손월령%원숙려%손파%풍복빈%전설
急性冠状动脉综合征%盐酸替罗非班%血小板聚集率%C反应蛋白
急性冠狀動脈綜閤徵%鹽痠替囉非班%血小闆聚集率%C反應蛋白
급성관상동맥종합정%염산체라비반%혈소판취집솔%C반응단백
Acute coronary syndrome%Tirofiban hydrochloride%Platelet aggregation rate%C reactive protein
目的 观察盐酸替罗非班对急性冠状动脉综合征(ACS)患者血小板聚集率、C反应蛋白(CRP)水平的影响.方法 将102例ACS患者完全随机分为常规治疗组(51例)和替罗非班组(51例).常规治疗组给予抗凝、抗血小板、调脂等常规药物治疗;替罗非班组在常规治疗的基础上,静脉滴注盐酸替罗非班48 h.治疗前后测定2组患者血浆二磷酸腺苷诱导的血小板聚集率、血清CRP水平,记录2组患者30 d随访期间心血管事件发生情况.结果 替罗非班组和常规治疗组治疗前血小板聚集率及血清CRP水平差异均无统计学意义[分别为(48±10)％比(50±12)％,(17.8±2.6) mg/L比(18.7±1.7) mg/L,均P＞0.05];替罗非班组和常规治疗组治疗后血小板聚集率及CRP水平分别为(12±6)％、(4.3±2.2) mg/L;(26±13)％、(9.3 ± 2.6) mg/L,均较治疗前明显下降(P＜0.01);2组治疗后比较差异有统计学意义(P＜0.01).随访30 d主要心血管事件心力衰竭、顽固性心绞痛发作、再发心肌梗死、全因死亡等,替罗非班组和常规治疗组比较差异均无统计学意义[2.0％ (1/51)比3.9％ (2/51),3.9％ (2/51)比5.9％ (3/51),0比2.0％(1/51),0比0](均P＞0.05).治疗期间,2组均无出血不良反应及大出血并发症发生.结论 ACS患者应用盐酸替罗非班可更迅速、有效地抑制血小板聚集,并能降低CRP水平.
目的 觀察鹽痠替囉非班對急性冠狀動脈綜閤徵(ACS)患者血小闆聚集率、C反應蛋白(CRP)水平的影響.方法 將102例ACS患者完全隨機分為常規治療組(51例)和替囉非班組(51例).常規治療組給予抗凝、抗血小闆、調脂等常規藥物治療;替囉非班組在常規治療的基礎上,靜脈滴註鹽痠替囉非班48 h.治療前後測定2組患者血漿二燐痠腺苷誘導的血小闆聚集率、血清CRP水平,記錄2組患者30 d隨訪期間心血管事件髮生情況.結果 替囉非班組和常規治療組治療前血小闆聚集率及血清CRP水平差異均無統計學意義[分彆為(48±10)％比(50±12)％,(17.8±2.6) mg/L比(18.7±1.7) mg/L,均P＞0.05];替囉非班組和常規治療組治療後血小闆聚集率及CRP水平分彆為(12±6)％、(4.3±2.2) mg/L;(26±13)％、(9.3 ± 2.6) mg/L,均較治療前明顯下降(P＜0.01);2組治療後比較差異有統計學意義(P＜0.01).隨訪30 d主要心血管事件心力衰竭、頑固性心絞痛髮作、再髮心肌梗死、全因死亡等,替囉非班組和常規治療組比較差異均無統計學意義[2.0％ (1/51)比3.9％ (2/51),3.9％ (2/51)比5.9％ (3/51),0比2.0％(1/51),0比0](均P＞0.05).治療期間,2組均無齣血不良反應及大齣血併髮癥髮生.結論 ACS患者應用鹽痠替囉非班可更迅速、有效地抑製血小闆聚集,併能降低CRP水平.
목적 관찰염산체라비반대급성관상동맥종합정(ACS)환자혈소판취집솔、C반응단백(CRP)수평적영향.방법 장102례ACS환자완전수궤분위상규치료조(51례)화체라비반조(51례).상규치료조급여항응、항혈소판、조지등상규약물치료;체라비반조재상규치료적기출상,정맥적주염산체라비반48 h.치료전후측정2조환자혈장이린산선감유도적혈소판취집솔、혈청CRP수평,기록2조환자30 d수방기간심혈관사건발생정황.결과 체라비반조화상규치료조치료전혈소판취집솔급혈청CRP수평차이균무통계학의의[분별위(48±10)％비(50±12)％,(17.8±2.6) mg/L비(18.7±1.7) mg/L,균P＞0.05];체라비반조화상규치료조치료후혈소판취집솔급CRP수평분별위(12±6)％、(4.3±2.2) mg/L;(26±13)％、(9.3 ± 2.6) mg/L,균교치료전명현하강(P＜0.01);2조치료후비교차이유통계학의의(P＜0.01).수방30 d주요심혈관사건심력쇠갈、완고성심교통발작、재발심기경사、전인사망등,체라비반조화상규치료조비교차이균무통계학의의[2.0％ (1/51)비3.9％ (2/51),3.9％ (2/51)비5.9％ (3/51),0비2.0％(1/51),0비0](균P＞0.05).치료기간,2조균무출혈불량반응급대출혈병발증발생.결론 ACS환자응용염산체라비반가경신속、유효지억제혈소판취집,병능강저CRP수평.
Objective To observe the influence of tirofiban hydrochloride on platelet aggregation rate and levels of C reactive protein (CRP) in patients with acute coronary syndrome (ACS).Methods The patients with ACS (n =102) were randomly divided into routine group (n =51) and tirofiban group (n =51).The routine group was treated with routine medications with anticoagulation,antiplatelet and regulating lipid; tirofiban group was given tirofiban hydrochloride plus routine medications for 48 hours.The platelet aggregation rate induced by plasma ADP and level of CRP were detected before and after tirofiban administration.The recurrent cardiovascular events were recorded during 30-day follow-up in two groups.Results Before treatment,there was no significant difference in platelet aggregation rate and serum CRP levels in tirofiban group and routine group [(48±10)％ vs (50±12)％,(17.8±2.6)mg/Lvs (18.7 ± 1.7)mg/L,respectively,P＞0.05].The levels of platelet aggregation rate and serum CRP after treatment in tirofiban group and routine group were (12 ± 6) ％,(4.3 ± 2.2) mg/L; (26 ± 13) ％,(9.3 ± 2.6) mg/L,respectively.The amplitude of platelet aggregation rate and serum CRP levels were significantly decreased in tirofiban group than those in routine group(P ＜ 0.01).There were no differences in bleeding adverse reactions and 30-day recurrent cardiovascular events between tirofiban group and routine group[2.0％ (1/51) vs 3.9％ (2/51),3.9％ (2/51) vs 5.9％ (3/51),0 vs 2.0％ (1/51),0 vs 0] (all P ＞ 0.05).Conclusions The administration of tirofiban in patients with ACS can rapidly and effectively inhibit platelet aggregation and decrease CRP level.Tirofiban hydrochloride can also stabilize plaque by inhibiting vascular inflammation.
